FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128266410> ?p ?o ?g. }

• W2128266410 endingPage "26" @default.
• W2128266410 startingPage "17" @default.
• W2128266410 abstract "BACKGROUND: Pravastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It prevents mevalonate synthesis, reducing endogenous cholesterol production, and reduces cholesterol content in the liver, thus resulting in a down-regulation of low-density lipoprotein receptor production. Gemfibrozil reduces very low-density lipoprotein production and low-density lipoprotein-cholesterol level and increases very low-density lipoprotein catabolism. Therefore, it was suggested that combination therapy with both drugs could effect greater reduction of cholesterol levels as compared to pravastatin alone. The present study was carried out to evaluate the efficacy and safety of pravastatin as a monotherapy or in combination with gemfibrozil in the treatment of patients with familial type IIb hyperlipoproteinemia or familial combined hyperlipidemia. METHODS AND RESULTS: Forty-one patients were included in the study. All patients initially followed 6 weeks of hypolipidemic diet; subsequently they were randomized and received either 20 mg once daily of pravastatin alone (n = 13) or 20 mg of pravastatin together with 600 mg of gemfibrozil twice daily (n = 14). As a control, 14 patients were treated with diet only. The treatment lasted 24 months and clinical evaluation and laboratory tests were done at given time points. Both groups of treated patients showed an early reduction (3 months) of total (about 30% P <.01 vs controls), low-density lipoprotein (about 35%, P <.01 vs controls) and very low-density lipoprotein cholesterol levels (about 18%, P = NS). In contrast, high-density lipoprotein cholesterol levels increased significantly in patients treated with pravastatin and gemfibrozil (about 20%, P <.05 vs controls). Pravastatin treatment alone reduced the level of serum triglycerides as efficiently as in combination with gemfibrozil. Data showed a sustained normalization of lipid profile until 24 months. However, this effect was achieved in patients that had rather low levels of triglycerides. During the treatment we did not observe any difference in the incidence of possible drug-related side effects. Severe myopathy or rhabdomyolysis was not observed at the doses of the drugs used in our study. CONCLUSIONS: Therapy with pravastatin and in combination with gemfibrozil resulted in significant and sustained normalization of lipid profile in high-risk patients with familial type IIb hyperlipoproteinemia or familial combined hyperlipidemia." @default.
• W2128266410 created "2016-06-24" @default.
• W2128266410 creator A5041185771 @default.
• W2128266410 creator A5050121158 @default.
• W2128266410 creator A5051324603 @default.
• W2128266410 creator A5061269136 @default.
• W2128266410 creator A5067875966 @default.
• W2128266410 date "1997-03-01" @default.
• W2128266410 modified "2023-09-27" @default.
• W2128266410 title "Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia" @default.
• W2128266410 cites W138991624 @default.
• W2128266410 cites W1834321439 @default.
• W2128266410 cites W1963505860 @default.
• W2128266410 cites W1969927159 @default.
• W2128266410 cites W1981729914 @default.
• W2128266410 cites W1983845042 @default.
• W2128266410 cites W1987225048 @default.
• W2128266410 cites W2000299078 @default.
• W2128266410 cites W2008590653 @default.
• W2128266410 cites W2022101016 @default.
• W2128266410 cites W2023732057 @default.
• W2128266410 cites W2025139995 @default.
• W2128266410 cites W2032022098 @default.
• W2128266410 cites W2048552473 @default.
• W2128266410 cites W2049310219 @default.
• W2128266410 cites W2051623738 @default.
• W2128266410 cites W2051989008 @default.
• W2128266410 cites W2052197491 @default.
• W2128266410 cites W2055676255 @default.
• W2128266410 cites W2059403223 @default.
• W2128266410 cites W2059839825 @default.
• W2128266410 cites W2063421142 @default.
• W2128266410 cites W2070547707 @default.
• W2128266410 cites W2081995474 @default.
• W2128266410 cites W2085733667 @default.
• W2128266410 cites W2085812846 @default.
• W2128266410 cites W2091214663 @default.
• W2128266410 cites W2109073239 @default.
• W2128266410 cites W2111591011 @default.
• W2128266410 cites W2116404316 @default.
• W2128266410 cites W2117594247 @default.
• W2128266410 cites W2133945578 @default.
• W2128266410 cites W2142802148 @default.
• W2128266410 cites W2143465004 @default.
• W2128266410 cites W2145512527 @default.
• W2128266410 cites W2156465277 @default.
• W2128266410 cites W2159042889 @default.
• W2128266410 cites W2299951426 @default.
• W2128266410 cites W2317657624 @default.
• W2128266410 cites W2341586442 @default.
• W2128266410 cites W2580938003 @default.
• W2128266410 cites W4212813430 @default.
• W2128266410 cites W4248021162 @default.
• W2128266410 cites W4249556169 @default.
• W2128266410 cites W4254363271 @default.
• W2128266410 cites W4292856541 @default.
• W2128266410 cites W4322700690 @default.
• W2128266410 doi "https://doi.org/10.1177/107424849700200103" @default.
• W2128266410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10684438" @default.
• W2128266410 hasPublicationYear "1997" @default.
• W2128266410 type Work @default.
• W2128266410 sameAs 2128266410 @default.
• W2128266410 citedByCount "16" @default.
• W2128266410 countsByYear W21282664102012 @default.
• W2128266410 countsByYear W21282664102013 @default.
• W2128266410 countsByYear W21282664102014 @default.
• W2128266410 countsByYear W21282664102015 @default.
• W2128266410 crossrefType "journal-article" @default.
• W2128266410 hasAuthorship W2128266410A5041185771 @default.
• W2128266410 hasAuthorship W2128266410A5050121158 @default.
• W2128266410 hasAuthorship W2128266410A5051324603 @default.
• W2128266410 hasAuthorship W2128266410A5061269136 @default.
• W2128266410 hasAuthorship W2128266410A5067875966 @default.
• W2128266410 hasConcept C104950815 @default.
• W2128266410 hasConcept C126322002 @default.
• W2128266410 hasConcept C134018914 @default.
• W2128266410 hasConcept C134651460 @default.
• W2128266410 hasConcept C181199279 @default.
• W2128266410 hasConcept C185592680 @default.
• W2128266410 hasConcept C2777320049 @default.
• W2128266410 hasConcept C2778163477 @default.
• W2128266410 hasConcept C2778670441 @default.
• W2128266410 hasConcept C2779091943 @default.
• W2128266410 hasConcept C2779519902 @default.
• W2128266410 hasConcept C2779620165 @default.
• W2128266410 hasConcept C2780072125 @default.
• W2128266410 hasConcept C55493867 @default.
• W2128266410 hasConcept C555293320 @default.
• W2128266410 hasConcept C71924100 @default.
• W2128266410 hasConcept C90924648 @default.
• W2128266410 hasConceptScore W2128266410C104950815 @default.
• W2128266410 hasConceptScore W2128266410C126322002 @default.
• W2128266410 hasConceptScore W2128266410C134018914 @default.
• W2128266410 hasConceptScore W2128266410C134651460 @default.
• W2128266410 hasConceptScore W2128266410C181199279 @default.
• W2128266410 hasConceptScore W2128266410C185592680 @default.
• W2128266410 hasConceptScore W2128266410C2777320049 @default.
• W2128266410 hasConceptScore W2128266410C2778163477 @default.

• next